Factors Influencing the Use and Interpretation of Animal Models in the Development of Parenteral Drug Delivery Systems

被引:0
作者
Marilyn N. Martinez
机构
[1] US FDA/Center for Veterinary Medicine,
来源
The AAPS Journal | 2011年 / 13卷
关键词
animal model; interspecies differences; parenteral drug delivery; pharmacokinetics;
D O I
暂无
中图分类号
学科分类号
摘要
Depending upon the drug and drug delivery platform, species-specific physiological differences can lead to errors in the interspecies extrapolation of drug performance. This manuscript provides an overview of the species-specific physiological variables that can influence the performance of parenteral dosage forms such as in situ forming delivery systems, nanoparticles, microspheres, liposomes, targeted delivery systems, lipophilic solutions, and aqueous suspensions. Also discussed are those factors that can influence the partitioning of therapeutic compounds into tumors, the central nervous system and the lymphatics. Understanding interspecies differences in the movement and absorption of molecules is important to the interpretation of data generated through the use of animal models when studying parenteral drug delivery.
引用
收藏
页码:632 / 649
页数:17
相关论文
共 394 条
  • [11] Pis A(2006)Hyaluronidase: a review of approved formulations, indications and off-label use in chronic pain management Ann Otol Rhinol Laryngol 115 156-164
  • [12] Alvarez L(1983)Quantitative and comparative studies of the vocal fold extracellular matrix. I: elastic fibers and hyaluronic acid Exp Eye Res 36 481-492
  • [13] Virkel G(2006)The molecular weight of hyaluronate in the aqueous humour and vitreous body of rabbit and cattle eyes Eur J Cell Biol 85 699-715
  • [14] Sanchez S(2004)Hyaluronan fragments: an information-rich system Nat Rev Cancer 4 528-539
  • [15] Sallovitz J(2008)Hyaluronan: from extracellular glue to pericellular cue Semin Cancer Biol 18 244-250
  • [16] Hirano K(2009)Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells Inflamm Allergy Drug Targets 8 208-220
  • [17] Yamada H(2004)CD44 and its role in inflammation and inflammatory diseases Arch Immunol Ther Exp (Warsz) 52 13-26
  • [18] Larsen C(2008)Recent advances in the regulation of CD44 expression and its role in inflammation and autoimmune diseases Mol Pharm 5 474-486
  • [19] Larsen SW(2010)Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor J Control Release 141 2-12
  • [20] Jensen H(2001)Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives Cancer Res 61 2592-2601